- Trials with a EudraCT protocol (22)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
22 result(s) found for: Biological indicator.
Displaying page 1 of 2.
EudraCT Number: 2016-005117-44 | Sponsor Protocol Number: 205240 | Start Date*: 2017-03-10 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A Phase 3b, Open-Label, Randomized, Multicenter Study to Assess the Safety and Immunogenicity of Novartis Meningococcal group B Vaccine When Administered Concomitantly with Novartis MenACWY Conjuga... | ||
Medical condition: Healthy volunteers (Infections, Meningoccal) | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-005568-14 | Sponsor Protocol Number: V72_60 | Start Date*: 2015-06-08 |
Sponsor Name:Novartis Pharma Services A.G. | ||
Full Title: A Phase 3, Open Label, Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Concomitantly With Rout... | ||
Medical condition: Prophylaxis of meningococcal meningitiditis caused by Neisseria meningitidis bacterium, serogroup B | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2023-000764-58 | Sponsor Protocol Number: 219967 | Start Date*: 2023-10-03 |
Sponsor Name:GlaxoSmithKline Biologicals SA | ||
Full Title: A Phase 4, single-arm, open-label, multi-center study to assess the immune response and safety of the meningococcal Group B vaccine MenB+OMV NZ when administered to healthy infants from 2 months of... | ||
Medical condition: Healthy volunteers (active immunization of infants against invasive meningococcal disease (IMD) due to N. meningitidis serogroup B infection). | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: (No results available) |
EudraCT Number: 2014-005083-15 | Sponsor Protocol Number: V72_42 | Start Date*: 2014-12-03 |
Sponsor Name:Novartis Vaccines and Diagnostics S.r.l. | ||
Full Title: A Phase 3, Randomized, Observer-blind, Multicenter Study to Evaluate the Immunogenicity and Safety of Novartis rMenB+OMV NZ Vaccine in Healthy Subjects Aged 11 to 17 years in Korea. | ||
Medical condition: Prophylaxis Aganist Invasive Group B Meningococcal Disease | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2011-003943-23 | Sponsor Protocol Number: SP848-AK-1101 | Start Date*: 2012-03-29 | |||||||||||
Sponsor Name:Spirig Pharma AG | |||||||||||||
Full Title: Prospective, randomized, partly blinded, in part placebo-controlled, multicenter, dose-finding trial exploring safety, tolerability and efficacy of a topical resiquimod gel in patients with multipl... | |||||||||||||
Medical condition: Actinic Keratosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001670-33 | Sponsor Protocol Number: 215344 | Start Date*: 2022-02-07 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: A Phase IIb, Randomized, Observer-Blind study to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents | |||||||||||||
Medical condition: Healthy volunteers (Active immunization against IMD caused by N.meningitidis serogroups A, B, C, W and Y) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001367-24 | Sponsor Protocol Number: 217043 | Start Date*: 2021-11-16 | |||||||||||
Sponsor Name:GlaxoSmithKline SA | |||||||||||||
Full Title: A Phase II, randomized, partially blinded study to assess the safety, tolerability and immunogenicity of meningococcal combined ABCWY vaccine when administered to healthy infants. | |||||||||||||
Medical condition: Healthy volunteers (Active immunization against IMD caused by Neisseria Meningitidis (N.meningitidis) serogroups A, B, C, W and Y) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Temporarily Halted) DE (Trial now transitioned) PL (Trial now transitioned) IT (Completed) FI (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000447-27 | Sponsor Protocol Number: USKH_VL1 | Start Date*: 2012-07-25 |
Sponsor Name:Universitätsklinikum Schleswig-Holstein, Campus Kiel | ||
Full Title: Open Label Study for the Functional Characterization of Drug Metabolism and Transport in patients before routine visceral surgery | ||
Medical condition: Pharmacokinetic trial in patients, with a good general condition before standard abdominal surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Temporarily Halted) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003042-47 | Sponsor Protocol Number: InsulaTOP | Start Date*: 2015-12-16 | |||||||||||
Sponsor Name:Centre Hospitalier Henri Laborit | |||||||||||||
Full Title: Psycho-biological substrates of therapeutic benefit of thermal cure on Generalized Anxiety Disorders | |||||||||||||
Medical condition: Generalised Anxiety Disorders | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004741-37 | Sponsor Protocol Number: 212458 | Start Date*: 2021-06-21 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A Phase I/II, randomised, controlled study to assess the safety, effectiveness and immune response of meningococcal combined ABCWY vaccine when administered to healthy adults (Phase I) and to healt... | ||
Medical condition: Healthy volunteers (Active immunization against IMD caused by Neisseria Meningitidis (N.meningitidis) serogroups A, B, C, W and Y) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) FI (Completed) Outside EU/EEA PL (Completed) SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-005401-28 | Sponsor Protocol Number: AOI2021ME_PICKERING | Start Date*: 2022-01-26 |
Sponsor Name:University Hospital of Clermont-Ferrand | ||
Full Title: Effects of the combination of magnesium bisphosphonates versus bisphosphonates alone on bone remodeling: Randomized pilot clinical trial | ||
Medical condition: postmenopausal osteoporosis | ||
Disease: | ||
Population Age: Elderly | Gender: Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000093-11 | Sponsor Protocol Number: 205218 | Start Date*: 2017-02-08 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A Phase 3b, Open Label, Controlled, Multi-Center, Extension Study to Athe Persistence of Bactericidal Activity at 4 to 7.5 Years After Two Dose Primary Series of GlaxoSmithKline Biologicals Meningo... | ||
Medical condition: Healthy volunteers (Infections, Meningococcal) | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2018-003218-42 | Sponsor Protocol Number: RC18_0287 | Start Date*: 2019-01-16 |
Sponsor Name:CHU de Nantes | ||
Full Title: Phase 2 study evaluating MEchanisms of resistance on tumor tissue and Liquid biopsy in patients with EGFR mutated nonpretreated advanced Lung cancer Receiving OSimErtinib until and beyond radiologi... | ||
Medical condition: Locally advanced or metastatic Non-small-cell lung carcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000657-30 | Sponsor Protocol Number: V72_28E1 | Start Date*: 2013-05-30 | |||||||||||
Sponsor Name:Novartis Vaccines and Diagnostics s.r.l. | |||||||||||||
Full Title: A Phase IIIB, Open Label, Multi-Center Extension Study of V72_28 to assess antibody persistence, and the safety and tolerability of a booster dose after the completion of the vaccination course in ... | |||||||||||||
Medical condition: A phase IIIB, Open Label, Multi Center extension study of V72_28 to assess antibody persistence, and the safety and tolerability of a booster dose after the completion of the vaccination course in ... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003056-21 | Sponsor Protocol Number: WIRE | Start Date*: 2020-02-07 | ||||||||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge | ||||||||||||||||||
Full Title: Window-of-opportunity clinical trials platform for evaluation of novel treatment strategies in renal cell cancer. | ||||||||||||||||||
Medical condition: Surgically resectable renal cell cancer (Stage M0/M1) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000518-34 | Sponsor Protocol Number: 0107 | Start Date*: 2011-10-25 | |||||||||||
Sponsor Name:Rikshospitalet | |||||||||||||
Full Title: Effect of beta blockade on left ventricular remodeling and function in aortic regurgitation | |||||||||||||
Medical condition: The aim of the present study is therefore to assess the effect of a 6 month treatment with beta-blocker on left ventricular remodeling and function in patients with asymptomatic moderate to severe ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000276-38 | Sponsor Protocol Number: MIBIOTIMI | Start Date*: 2021-07-06 | |||||||||||
Sponsor Name:Álvaro Ruibal Morell | |||||||||||||
Full Title: Tumour heterogeneity studies based on dedicated breast PET using proliferation radiotracers: early detection of the treatment response | |||||||||||||
Medical condition: Breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000193-35 | Sponsor Protocol Number: MONAVI-1 | Start Date*: 2015-10-01 | |||||||||||
Sponsor Name:Centre François Baclesse | |||||||||||||
Full Title: A phase II study of ABT-263 as single agent in women with platinum resistant/refractory recurrent ovarian cancer | |||||||||||||
Medical condition: Platinum-resistant or refractory ovarian cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002766-31 | Sponsor Protocol Number: 1200.277 | Start Date*: 2018-11-23 | |||||||||||
Sponsor Name:UCL | |||||||||||||
Full Title: A phase 2, single arm, European multi-center trial evaluating the efficacy of afatinib as first line or later line treatment in advanced chordoma | |||||||||||||
Medical condition: Chordoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003407-38 | Sponsor Protocol Number: 8669-062 | Start Date*: 2012-01-23 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase I Study of Monotherapy Dalotuzumab and Ridaforolimus-Dalotuzumab Combination Treatment in Paediatric Patients with Advanced Solid Tumours | |||||||||||||
Medical condition: Advanced solid tumours including lymphoma and tumours of the central nervous system. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
